Rotavirus Live Vaccine
Brand names: Rotarix · Active ingredient: Human Rotavirus A Type G1P(8) Strain Rix4414 Live Antigen
In short: ROTARIX is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series . ROTARIX is approved for use in infants 6 weeks and up to 24 weeks of age.
What is Rotavirus Live Vaccine used for?
ROTARIX is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series . ROTARIX is approved for use in infants 6 weeks and up to 24 weeks of age.
Rotavirus Live Vaccine dosage
For oral use only.
Each dose is 1.5 mL.
Administer orally as a series of 2 doses beginning at 6 weeks of age. There should be an interval of at least 4 weeks between the first and second dose. The 2-dose series should be completed by 24 weeks of age.
Safety and effectiveness have not been evaluated if ROTARIX were administered for the first dose and another rotavirus vaccine were administered for the second dose or vice versa.
In the event that the infant spits out or regurgitates most of the vaccine dose, a single replacement dose may be considered at the same vaccination visit.
There are no restrictions on the infant’s liquid consumption, including breast milk, either before or after vaccination with ROTARIX.
ROTARIX, supplied in an oral dosing applicator, contains a ready-to-use liquid formulation. Each dose of 1.5 mL is administered orally. ROTARIX appears clear and colorless.
See below for preparation and administration steps.
Step 1: Remove the protective Tip Cap from the oral dosing applicator.
Do not pull the oral dosing applicator plunger out of the barrel. If it happens, do not administer the vaccine.
Step 2: For oral use only. Have the infant seated in a reclining position. Place the oral dosing applicator towards the inner cheek. Administer the entire contents of the oral dosing applicator into the infant’s mouth.
How to take Rotavirus Live Vaccine — instructions & advice from the label
See FDA-approved patient labeling (Patient Information). Patient labeling is provided as a tear-off leaflet at the end of this full prescribing information.
Provide the following information to the parent or guardian:
•Inform of the potential benefits and risks of immunization with ROTARIX, and of the importance of completing the immunization series.
•Inform about the potential for adverse reactions that have been temporally associated with administration of ROTARIX or other vaccines containing similar components.
•Instruct to immediately report any signs and/or symptoms of intussusception to their healthcare provider.
•Give the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).
Warnings & precautions
Do not take this medicine if: A demonstrated history of hypersensitivity to any component of the vaccine.
Infants who develop symptoms suggestive of hypersensitivity after receiving a dose of ROTARIX should not receive further doses of ROTARIX.
Infants with a history of uncorrected congenital malformation of the gastrointestinal tract (such as Meckel’s diverticulum) that would predispose the infant for intussusception should not receive ROTARIX.
Infants with a history of intussusception should not receive ROTARIX . In postmarketing experience, intussusception resulting in death following a second dose has been reported following a history of intussusception after the first dose .
Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive ROTARIX. Postmarketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered live, oral rotavirus vaccines and later identified as having SCID .
Administration of ROTARIX should be delayed in infants suffering from acute diarrhea or vomiting.
Safety and effectiveness of ROTARIX in infants with chronic gastrointestinal disorders have not been evaluated.
Safety and effectiveness of ROTARIX in infants with known primary or secondary immunodeficiencies, including infants with human immunodeficiency virus (HIV), infants on immunosuppressive therapy, or infants with malignant neoplasms affecting the bone marrow or lymphatic system have not been established. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune response to ROTARIX.
Rotavirus shedding in stool occurs after vaccination with peak excretion occurring around Day 7 after Dose 1. …
Rotavirus Live Vaccine side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.
Two formulations of ROTARIX were studied in clinical trials: a reconstituted lyophilized formulation (previously supplied in a vial and oral dosing applicator presentation) and a liquid formulation (supplied in an oral dosing applicator) . The reconstituted lyophilized formulation has been discontinued and is no longer marketed. The safety data accrued with the discontinued lyophilized formulation is relevant to the liquid formulation as both contain the same live, attenuated rotavirus strain and both formulations are manufactured using a similar process.
Common (≥5%) solicited adverse reactions included fussiness/irritability, cough/runny nose, fever, loss of appetite, and vomiting.
Solicited adverse reactions, unsolicited adverse events, serious adverse events (SAEs), and cases of intussusception were collected in 7 clinical studies (Studies 1 to 7; NCT00729001, NCT00385320, NCT00429481, NCT00757770, NCT00140686, NCT00169455, NCT00137930). Cases of intussusception and SAEs were collected in an additional large safety study (Study 8; NCT00140673) that compared ROTARIX (reconstituted lyophilized formulation) to placebo. …
About this medicine
ROTARIX (Rotavirus Vaccine, Live, Oral) is an orally administered live, attenuated rotavirus vaccine derived from the human 89-12 strain which belongs to G1P[8] type. The rotavirus vaccine strain is propagated on Vero cells.
ROTARIX is an oral solution available in a ready-to-use liquid formulation (supplied in an oral dosing applicator).
Each 1.5 mL dose of ROTARIX contains at least 106.0 Cell Culture Infective Dose (CCID50) of live, attenuated rotavirus.
ROTARIX contains disodium adipate, Dulbecco’s Modified Eagle Medium (DMEM), sucrose, and sterile water. DMEM contains the following ingredients: sodium chloride, potassium chloride, magnesium sulfate, ferric (III) nitrate, sodium dihydrogen phosphate, sodium pyruvate, D-glucose, concentrated vitamin solution, L-cystine, L-tyrosine, amino acids solution, L-glutamine, calcium chloride, and sodium hydrogenocarbonate.
ROTARIX contains an antacid component (disodium adipate) to protect the vaccine during passage through the stomach and prevent its inactivation due to the acidic environment of the stomach. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f3182470-1965-4e20-dbaf-e3506f893ea5. Read the full official label on DailyMed.